Rigor Reviewed

Rigor-Reviewed Manuscript

Nab-paclitaxel, cisplatin, and capecitabine versus cisplatin and gemcitabine as first line chemotherapy in patients with recurrent or metastatic nasopharyngeal carcinoma: randomised phase 3 clinical trial.

Name: Αlpha¹ Rigor Record — Nab-paclitaxel, cisplatin, and capecitabine versus cisplatin and gemcitabine as first line chemotherapy in patients with recurrent or metastatic nasopharyngeal carcinoma: randomised phase 3 clinical trial.
Item: Nab-paclitaxel, cisplatin, and capecitabine versus cisplatin and gemcitabine as first line chemotherapy in patients with recurrent or metastatic nasopharyngeal carcinoma: randomised phase 3 clinical trial.
Rating: 39
Author: Αlpha¹

Liu GY, Ye YF, Jiang YF, Chen GJ, Xia WX, Huang YS, Gao TS, Liu YM, Hou YT, Li JF, Liu JH, Lu N, Chen CL, Ke LR, Liang H, Bei WX, Li WZ, Dong SH, Liu Q, Xie C, Yao HR, Xiang YQ

Paper source

Read full text (PMC)

Embed this Rigor badge

Αlpha¹ Rigor Review — 1★ (Critical), 2 critical, 3 high issues for “Nab-paclitaxel, cisplatin, and capecitabine versus cisplatin and gemcitabine as first line chemotherapy in patients with recurrent or metastatic nasopharyngeal carcinoma: randomised phase 3 clinical trial.”

Links back to this Rigor Record.

Αlpha¹ Editorial

This rigor review was examined and confirmed by Αlpha¹ Editorial · August 16, 2026

Αlpha¹ Rigor Review

Rigor Reviewed

1 / 5

Critical — a demonstrable failure

Interventional Study

Critical

High-priority

How this rating was calculated▸

Started at 5★ — deductions

StatisticsImpossible or misreported statistic ×4−4★
IntegrityIntegrity concern−0.5★
ClaimsOverstated claim−0.5★
ClaimsEfficacy rests on an unvalidated surrogate endpoint−0.5★
ClaimsTreatment effect not shown to be clinically meaningful−0.5★
ReportingData & code availability partially met−0.25★

A demonstrable critical failure caps the rating at the minimum, regardless of the deductions above.

Model-reported confidence: highReviewer agreement: highEngine: 7.39.0Source: full text

Not verified in this report

No data or code availability links were detected to verify.

Problems surfaced6 types

Numerical inconsistencies2

Values that contradict each other or are impossible for the stated sample: recomputed p-values and test statistics, GRIM/GRIMMER checks on summary numbers, percentages against their own counts, totals against their parts, and estimates against their own confidence intervals.

Summary statistic impossible for the stated N (GRIM/GRIMMER)Recomputed
Internal contradictions in the reported numbersAssessed

Overstated conclusions3

Conclusions that reach past what the paper's own results support — including a significance claim that no longer holds when the statistic is recomputed, and efficacy resting on an unvalidated surrogate endpoint.

Efficacy rests on an unvalidated surrogate endpointAssessed
Treatment effect not shown to be clinically meaningfulAssessed
Conclusions overstated beyond the evidenceAssessed

Reporting gaps1

Required detail the manuscript never states — study design, biological variables, ethics approval and consent, key resources, statistical reporting, data and code availability, and overall transparency.

Data/code availability incompleteAssessed

This Αlpha¹ Rigor Review uses AI Rigor Reviewers trained on a curated corpus of high-fidelity and retracted papers, with expert supervision and curation. It can still make mistakes; verify each finding against the source before relying on it.

Critical findings

• PERCENT: 98% does not match the reported count 1/41
• PERCENT: 92.5% does not match the reported count 3/40
• PERCENT: 98% does not match the reported count 1/41
• PERCENT: 92.5% does not match the reported count 3/40

This is a well-conducted phase 3 randomised controlled trial with rigorous design, clear ethical approvals, and appropriate statistical methods. The main weaknesses are the vague data availability statement, lack of explicit reporting guideline adherence, and a slightly overstated conclusion given the interim nature of the analysis.

Both reviewers agreed on all dimensions and study type (interventional). The statistics verification component could only recompute a subset of tests (8 of 12 reported with sufficient detail); the remaining 4 were threshold-only or resampling-based and could not be machine-verified, so no claim of overall statistical correctness is made. The citation check found no retracted or unresolved references.

5 major claims checked against the paper's own evidence: 1 not fully backed by the presented evidence (unsupported or overstated).

Premise concern: surrogate not validated for clinical benefit; effect size not shown to be clinically meaningful.

Recomputed 8 tests: 8 consistent, 0 inconsistent; 1 recomputed directly from the reported test statistics, 7 via agent-written checks. 4 reported summary statistics mathematically impossible for the stated N (PERCENT).

1 integrity concern flagged (0 high).

Reporting

Eight Dimensions7 pass · 1 warn

The introduction cites the landmark phase 3 trial establishing gemcitabine plus cisplatin as standard, notes the limited median progression-free survival of 7.0-7.7 months, and references prior work on capecitabine maintenance and nab-paclitaxel. The rationale for the study follows logically from these findings. Limitations of prior research are implicitly addressed by the design of a new regimen to improve efficacy.

Sub-criteria

prior work citedADEQUATE

premise rationaleADEQUATE

limitations addressedADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

The study clearly establishes the scientific premise by citing prior research on the standard gemcitabine plus cisplatin regimen and the rationale for testing nab-paclitaxel-based triplet therapy.

Evidence

direct quote[Introduction, paragraph 2]

“A phase 3 study has shown that gemcitabine plus cisplatin prolongs progression-free survival and overall survival in comparison with 5-fluorouracil plus cisplatin, which led to the establishment of gemcitabine plus cisplatin as the front line regimen for recurrent or metastatic nasopharyngeal carcinoma.”